1. Freedman LS, Clifford C, Messina M. Analysis of dietary fat, calories, body weight and the development of mammary tumors in rats and mice: a review. Cancer Res. 1990;50:5710-5719.
2. Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiologic data and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control. 1990;1:81-97.
3. Howe GR, Hirohata T, Hislop TG, et al. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst. 1990;82: 561-569.
4. Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer: a pooled analysis. N Engl J Med. 1996;334:356- 361.
5. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer. 2003;89:1672-1685.
6. Heitmann BL, Lissner L. Dietary underreporting by obese individuals: is it specific or non-specific. BMJ. 1995;311:986-989.
7. Subar AF, Kipnis V, Troiano RP, et al. Using intake biomarkers to evaluate the extent of dietary misreporting in a large sample of adults: the OPEN study.Am J Epidemiol. 2003;158:1-13.
8. Day NE, McKeown N, Wong MY, Welch A, Bingham S. Epidemiologic a sessment of diet: a comparison of a 7-day diary with a food frequency questionnaire using urinary markers of nitrogen, potassium and sodium. Int J Epidemiol. 2001;30:309-317.
9. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N. Are imprecise methods obscuring a relation between fat and breast cancer. Lancet. 2003;362: 212-214.
10. Insull W, Henderson MM, Prentice RL, et al. Results of a randomized feasibility study of a low-fat diet. Arch Intern Med. 1990;150:421-427.
11. Coates RJ, Bowen DJ, Kristal AR, et al. The Women’s Health Trial Feasibility Study in minority populations: changes in dietary intakes.AmJ Epidemiol. 1999; 149:1104-1112.
12. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D. Dietary fat reduction and plasma estradiol concentration among healthy postmenopausal women. J Natl Cancer Inst. 1990;82:129-134.
13. Rose DP, Connolly JM, Chlebowski RT, Buzzard IM, Wynder EL. The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients.Breast Cancer Res Treat. 1993;27:253-262.
14. Rock CL, Flatt SW, Thompson CA, et al. Effects of a high-fiber, low-fat diet intervention on serum concentrations of reproductive steroid hormones in women with a history of breast cancer. J Clin Oncol. 2004;22: 2379-2387.
15. WuAH, Pike MC, Stramm DO. Meta-analysis: dietary fat intake, serum estrogen levels, and risk of breast cancer. J Natl Cancer Inst. 1999;91:529-534.
16. World Cancer Research Fund. Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 1997.
17. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 2001; 285:769-776.
18. Gandini S, Merzenich H, Robertson C, Boyle P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and Vegetable consumption and the intake of associated micronutrients. Eur J Cancer. 2000; 36:636-646.
19. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr. 2003;78(suppl 3):559S-569S.
20. Working IARC Group on the Evaluation of Cancer-Preventive Strategies. Fruit and vegetables In: IARC Handbooks of Cancer Prevention: Vol. 8. Lyon, France: International Agency for Research on Cancer; 2003.
21. Chatenoud L, Tavani A, La Vecchia C, et al. Whole grain food intake and cancer risk. Int J Cancer. 1998; 77:24-28.
22. Jacobs DR, Marquent L, Slavin J, Kischi LH. Whole grain intake and cancer: an expanded review and meta-analysis. Nutr Cancer. 1998;30:85-96.
23. Nicodemus KK, Jacobs DR Jr, Folsom AR. Wholeand refined grain and risk of incident postmenopausal breast cancer (United States). Cancer Causes Control. 2001;12:917-925.
24. Kipnis V, Midthune D, Freedman LS, et al. Empirical evidence of correlated biases in dietary assessment instruments and its implications.AmJ Epidemiol. 2001;153:394-403.
25. Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
26. Ritenbaugh C, Patterson R, Chlebowski RT, et al. The Women’s Health Initiative Dietary Modification Trial: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9S):S87-S97.
27. Hays J, Hunt JR, Hubbell FA, et al. The Women’s Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9S):S18-S77.
28. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
29. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701-1712.
30. Patterson RE, Kristal AR, Tinker LF, et al. Measurement characteristics of the Women’s Health Initiative food frequency questionnaire. Ann Epidemiol. 1999;9:178-187.
31. Tinker L, Burrows E, Henry H, Patterson R, Rupp J, Van Horn L. The Women’s Health Initiative: overview of the nutrition components. In: Krummel DA, Kris-Etherton PM, eds. Nutrition in Women’s Health. Gaithersburg, Md: Aspen Publishers; 1996:510-549.
32. Nutrition and Your Health: Dietary Guidelines for Americans. 3rd ed. Washington, DC: US Dept of Health and Human Services; 1990.
33. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol. 2003; 13(9S):S122-S128.
34. Cox DR. Regression analysis and life tables. J R Stat Soc B. 1972;34:187-220.
35. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779-781.
36. Piegorsch WW, Weinberg CR, Taylor JA. Nonhierarchical logistic models and case-only designs for assessing susceptibility in population-based casecontrol studies. Stat Med. 1994;13:153-162.
37. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York, NY: John Wiley & Sons Inc; 2002:255.
38. O’Brien PC, Fleming RT. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
39. Freedman L, Anderson G, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women’s Health Initiative. Control Clin Trials. 1996;17:509-525.
40. Women’s Health Initiative Study Group. Dietary adherence in the Women’s Health Initiative Dietary Modification Trial. J Am Diet Assoc. 2004;104: 654-658.
41. Chlebowski RT, Blackburn GL, Elashoff RE, et al. Dietary fat reduction in postmenopausal women with primary breast cancer: phase III Women’s Intervention Nutrition Study (WINS) [abstract]. Proc Am Soc Clin Oncol. 2005;23(16S):3S. Abstract 10.
42. Fung TT, Hu FB, Holmes MD, et al. Dietary patterns and the risk of postmenopausal breast cancer. Int J Cancer. 2005;116:116-121.
43. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet. 2005;365:1687-1717.
44. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431-2442.
45. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med. 2005;353:1673-1684.
46. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med. 2005;353:1659-1672.
47. Rouzier R, Perou DM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
48. ATAC Trialist Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
49. Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women’s Heart and Health Study. Cancer Causes Control. 2004;15:267-275.
50. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer. 2000;88:828-832.
51. Patterson RE, Kristal A, Rodabough R, et al. Changes in food sources of dietary fat in response to an intensive low-fat dietary intervention: early results from the Women’s Health Initiative. J Am Diet Assoc. 2003;103:454-460.